Non-alcoholic Steatohepatitis Market
Non-alcoholic Steatohepatitis Market Scope:
Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Non-alcoholic Steatohepatitis Market Size and Growth
The Non-alcoholic Steatohepatitis (NASH) market is expanding, driven by rising obesity rates and increased awareness. The market is projected to reach approximately $30 billion by 2026. Key trends include innovative drug developments and improving diagnostic tools, highlighting a significant opportunity for stakeholders to address this growing health concern effectively.
Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ AstraZeneca
◍ Arena Pharmaceuticals
◍ GSK
◍ Novo Nordisk
◍ Roche
◍ Vivus
◍ Arisaph Pharmaceuticals
◍ Cempra Pharmaceuticals
◍ Galectin Therapeutics
◍ Galmed Pharmaceuticals
◍ Genfit
◍ Gilead
◍ Immuron
◍ Interceptpharma
◍ Raptor Pharmaceutical
◍ Takeda
◍ Tobira Therapeutics
The Non-alcoholic Steatohepatitis (NASH) market features key players like AstraZeneca, GSK, and Roche, developing therapies to address this liver disease. These companies enhance market growth through innovative drug developments, clinical trials, and strategic partnerships. Sales revenue of some companies includes AstraZeneca: $37B, GSK: $44B, Roche: $64B.
◍ Verva
Request Sample Report
Market Segmentation
By Application
Request Sample Report
By Product
Market Growth
Request Sample Report
$ X Billion USD
